Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00670592 · ClinicalTrials.gov registry record · Phase 1
Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 111
- Enrollment target
NCT00670592 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 111 participants.
The verdict
NCT00670592, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 111 participants
- Enrollment target
Study Summary
This study is to evaluate the highest tolerated dose, safety and activity of HCD122 in adults with non-Hodgkin's or Hodgkin's lymphoma who have received at least two prior therapies.
Interventions
- DRUG HCD122
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2008-03 |
| Est. Completion | 2013-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00670592
The ClinicalTrials.gov registry entry for NCT00670592 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HCD122 is the first listed.
NCT00670592 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00670592 about?
NCT00670592 is a clinical study titled "Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies". This study is to evaluate the highest tolerated dose, safety and activity of HCD122 in adults with non-Hodgkin's or Hodgkin's lymphoma who have received at least two prior therapies.
What is the current status of trial NCT00670592?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 111 participants. The study started on 2008-03. Estimated completion is 2013-02.
What interventions are being tested in trial NCT00670592?
The interventions under investigation include: HCD122 (DRUG).
Who is sponsoring clinical trial NCT00670592?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.